ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.
Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...
Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.
Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting first-line therapy are follicular lymphoma highlights from ASH 2025.
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh,75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback